{"id":745159,"date":"2015-06-29T07:30:00","date_gmt":"2015-06-29T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/"},"modified":"2025-11-07T01:25:05","modified_gmt":"2025-11-07T06:25:05","slug":"merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/","title":{"rendered":"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from a Phase 3 study investigating the safety<br \/>\n      and efficacy of single-dose EMEND<sup>\u00ae<\/sup> (fosaprepitant<br \/>\n      dimeglumine) for Injection, Merck\u2019s substance P\/neurokinin (NK-1)<br \/>\n      receptor antagonist, in combination with other anti-vomiting medicines,<br \/>\n      for the prevention of chemotherapy-induced nausea and vomiting (CINV) in<br \/>\n      adult cancer patients receiving moderately emetogenic (vomit-inducing)<br \/>\n      chemotherapy (MEC). In the study, the first to evaluate an intravenous<br \/>\n      NK-1 receptor antagonist for the prevention of CINV associated with MEC,<br \/>\n      the single-dose EMEND for Injection regimen provided greater protection<br \/>\n      from nausea and vomiting following administration of chemotherapy versus<br \/>\n      an active control of placebo with other anti-vomiting medicines. These<br \/>\n      data were presented in an oral session at the Multinational Association<br \/>\n      of Supportive Care in Cancer\/International Society of Oral Oncology<br \/>\n      (MASCC\/ISOO) Annual Meeting on <i>Supportive Care in Cancer<\/i><br \/>\n      (Abstract #27-02-O) in Copenhagen (June 25-27, 2015).\n    <\/p>\n<p>\n      \u201cThe results from this important Phase 3 trial are very encouraging as<br \/>\n      they are the first study to evaluate EMEND for Injection in a<br \/>\n      combination regimen for the prevention of chemotherapy-induced nausea<br \/>\n      and vomiting in patients receiving moderately emetogenic chemotherapy \u2013<br \/>\n      and show the potential to use a single day antiemetic regimen,\u201d said Dr.<br \/>\n      Bernardo L. Rapoport, principal investigator for the study and chief<br \/>\n      medical oncologist, Medical Oncology Centre of Rosebank, Johannesburg,<br \/>\n      South Africa.\n    <\/p>\n<p>\n      &#8220;Nausea and vomiting remain a significant burden for patients receiving<br \/>\n      chemotherapy and we look forward to submitting these data for EMEND for<br \/>\n      Injection to the U.S. Food and Drug Administration,\u201d said Stuart Green,<br \/>\n      vice president, clinical research, Merck Research Laboratories. \u201cThis<br \/>\n      study builds on our decade of research for EMEND and Merck\u2019s overall<br \/>\n      commitment to help people with cancer.\u201d\n    <\/p>\n<p>\n      EMEND for Injection, a substance P\/Neurokinin-1 (NK1) receptor<br \/>\n      antagonist approved for use in combination with other antiemetic agents,<br \/>\n      is indicated in adults for the prevention of acute and delayed nausea<br \/>\n      and vomiting associated with initial and repeat courses of highly<br \/>\n      emetogenic cancer (HEC) chemotherapy, including high-dose cisplatin; and<br \/>\n      for prevention of nausea and vomiting associated with initial and repeat<br \/>\n      courses of MEC. EMEND has not been studied for treatment of established<br \/>\n      nausea and vomiting. Chronic continuous administration of EMEND is not<br \/>\n      recommended.\n    <\/p>\n<p>\n      In the U.S., the single-dose regimen of EMEND for Injection is approved<br \/>\n      for use associated with HEC. Merck plans to submit these recent data to<br \/>\n      the Food and Drug Administration in the second half of 2015 to seek<br \/>\n      approval for a regimen containing single-dose EMEND for Injection for<br \/>\n      the prevention of CINV associated with MEC.\n    <\/p>\n<p>\n      <b>About Phase 3 Study for Single-Dose EMEND for Injection in MEC<\/b>\n    <\/p>\n<p>\n      In this global randomized, Phase 3, double-blind study, more than 1,000<br \/>\n      patients receiving MEC were randomly assigned to receive either<br \/>\n      single-dose EMEND for Injection (150 mg) in combination with ondansetron<br \/>\n      capsules (16 mg) and dexamethasone capsules (12 mg) (n=504) on day one<br \/>\n      (followed by oral placebo for ondansetron on days two and three) or an<br \/>\n      active control regimen consisting of placebo (saline IV) in combination<br \/>\n      with ondansetron (16 mg) and dexamethasone (20 mg) (n=497) on day one<br \/>\n      (followed by 8 mg ondansetron on days two and three). The primary<br \/>\n      endpoint of the study was complete response (CR) (as measured by no<br \/>\n      vomiting and no use of rescue medication for nausea or vomiting) in the<br \/>\n      delayed phase (25 to 120 hours following initiation of chemotherapy).<br \/>\n      The secondary endpoints were CR after the first dose of chemotherapy in<br \/>\n      the acute phase (0 to 24 hours) and in the overall phase (0-120 hours),<br \/>\n      as well as no vomiting in the overall phase.\n    <\/p>\n<p>\n      <b>Single-Dose EMEND for Injection Regimen Achieved Superior Control of<br \/>\n      CINV<\/b>\n    <\/p>\n<p>\n      For the primary study endpoint, EMEND for Injection regimen provided<br \/>\n      higher incidence of CR in days 2 through 5 \u2013 with CR observed in 78.9<br \/>\n      percent of patients receiving the EMEND for Injection regimen versus<br \/>\n      68.5 percent in the active control group (p &lt;0.001). For the secondary<br \/>\n      endpoints, in the acute phase, CR was observed in 93.2 percent of<br \/>\n      patients receiving the EMEND for Injection regimen versus 91 percent in<br \/>\n      the active control group (p = 0.184). In the overall phase, the<br \/>\n      incidence of CR was observed in 77.1 percent of patients receiving the<br \/>\n      EMEND for Injection regimen versus 66.9 percent in the active control<br \/>\n      group (p &lt;0.001). Additionally, a significantly greater proportion of<br \/>\n      patients receiving the EMEND for Injection regimen experienced no<br \/>\n      vomiting in the overall phase (82.7 percent with EMEND vs 72.9 percent<br \/>\n      in the active control group) and delayed phase (83.9 percent with EMEND<br \/>\n      vs 75.1 percent in the active control group) (both p &lt;0.001) \u2013 with a<br \/>\n      favorable trend in the acute phase (94.8 percent with EMEND vs 92<br \/>\n      percent in the active control group).\n    <\/p>\n<p>\n      The most common adverse events (across all grades) in the EMEND for<br \/>\n      Injection regimen and active control group included fatigue (15.1<br \/>\n      percent and 12.9 percent), diarrhea (12.7 percent and 11.3 percent), and<br \/>\n      constipation (9.3 percent and 10.5 percent). Treatment-related adverse<br \/>\n      events were observed in 8.5 percent of patients receiving the EMEND for<br \/>\n      Injection regimen and in 9.1 percent of patients in the active control<br \/>\n      group. Serious treatment-related adverse events were observed in 0.2<br \/>\n      percent of patients receiving the EMEND for Injection regimen and in 0.4<br \/>\n      percent of patients in the active control group.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for EMEND (fosaprepitant<br \/>\n      dimeglumine) For Injection<\/b>\n    <\/p>\n<p>\n      EMEND for Injection is contraindicated in patients who are<br \/>\n      hypersensitive to EMEND for Injection, aprepitant, polysorbate 80, or<br \/>\n      any other components of the product. Known hypersensitivity reactions<br \/>\n      include flushing, erythema, dyspnea, and anaphylactic reactions.\n    <\/p>\n<p>\n      Aprepitant, when administered orally, is a moderate cytochrome P450<br \/>\n      isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly<br \/>\n      converted to aprepitant, neither drug should be used concurrently with<br \/>\n      pimozide or cisapride. Inhibition of CYP3A4 by aprepitant could result<br \/>\n      in elevated plasma concentrations of these drugs, potentially causing<br \/>\n      serious or life-threatening reactions.\n    <\/p>\n<p>\n      EMEND for Injection should be used with caution in patients receiving<br \/>\n      concomitant medications, including chemotherapy agents that are<br \/>\n      primarily metabolized through CYP3A4. Inhibition of CYP3A4 by EMEND for<br \/>\n      Injection could result in elevated plasma concentrations of these<br \/>\n      concomitant medications. Conversely, when EMEND for Injection is used<br \/>\n      concomitantly with another CYP3A4 inhibitor, aprepitant plasma<br \/>\n      concentrations could be elevated. When EMEND for Injection is used<br \/>\n      concomitantly with medications that induce CYP3A4 activity, aprepitant<br \/>\n      plasma concentrations could be reduced, and this may result in decreased<br \/>\n      efficacy of aprepitant.\n    <\/p>\n<p>\n      Chemotherapy agents that are known to be metabolized by CYP3A4 include<br \/>\n      docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib,<br \/>\n      vinorelbine, vinblastine, and vincristine. In clinical studies, EMEND<br \/>\n      was administered commonly with etoposide, vinorelbine, or paclitaxel.<br \/>\n      The doses of these agents were not adjusted to account for potential<br \/>\n      drug interactions. In separate pharmacokinetic studies, EMEND did not<br \/>\n      influence the pharmacokinetics of docetaxel or vinorelbine.\n    <\/p>\n<p>\n      Because a small number of patients in clinical studies received the<br \/>\n      CYP3A4 substrates vinblastine, vincristine, or ifosfamide, particular<br \/>\n      caution and careful monitoring are advised in patients receiving these<br \/>\n      agents or other chemotherapy agents metabolized primarily by CYP3A4 that<br \/>\n      were not studied.\n    <\/p>\n<p>\n      There have been isolated reports of immediate hypersensitivity<br \/>\n      reactions, including flushing, erythema, dyspnea, and anaphylaxis,<br \/>\n      during infusion of fosaprepitant. These hypersensitivity reactions have<br \/>\n      generally responded to discontinuation of the infusion and<br \/>\n      administration of appropriate therapy. It is not recommended to<br \/>\n      reinitiate the infusion in patients who have experienced these symptoms<br \/>\n      during first-time use.\n    <\/p>\n<p>\n      Coadministration of EMEND for Injection with warfarin (a CYP2C9<br \/>\n      substrate) may result in a clinically significant decrease in<br \/>\n      international normalized ratio (INR) of prothrombin time. In patients on<br \/>\n      chronic warfarin therapy, the INR should be closely monitored in the<br \/>\n      2-week period, particularly at 7 to 10 days, following initiation of<br \/>\n      EMEND for Injection with each chemotherapy cycle.\n    <\/p>\n<p>\n      The efficacy of hormonal contraceptives (including birth control pills,<br \/>\n      skin patches, implants, and certain IUDs) may be reduced during<br \/>\n      coadministration with and for 28 days after the last dose of EMEND for<br \/>\n      Injection. Alternative or backup methods of contraception should be used<br \/>\n      during treatment with and for 1 month after the last dose of EMEND for<br \/>\n      Injection.\n    <\/p>\n<p>\n      Chronic continuous use of EMEND for Injection for prevention of nausea<br \/>\n      and vomiting is not recommended because it has not been studied and<br \/>\n      because the drug interaction profile may change during chronic<br \/>\n      continuous use.\n    <\/p>\n<p>\n      In clinical trials of EMEND in patients receiving HEC, the most common<br \/>\n      adverse events reported at a frequency greater than with standard<br \/>\n      therapy, and at an incidence of 1% or greater, were hiccups (4.6% EMEND<br \/>\n      vs 2.9% standard therapy), asthenia\/fatigue (2.9% vs 1.6%), increased<br \/>\n      ALT (2.8% vs 1.5%), increased AST (1.1% vs 0.9%), constipation (2.2% vs<br \/>\n      2.0%), dyspepsia (1.5% vs 0.7%), diarrhea (1.1% vs 0.9%), headache (2.2%<br \/>\n      vs 1.8%), and anorexia (2.0% vs 0.5%).\n    <\/p>\n<p>\n      In a clinical trial evaluating safety of the 1-day regimen of EMEND for<br \/>\n      Injection compared with the 3-day regimen of EMEND, the safety profile<br \/>\n      was generally similar to that seen in prior HEC studies with aprepitant.<br \/>\n      However, infusion-site reactions occurred at a higher incidence in<br \/>\n      patients who received fosaprepitant (3.0%) than in those who received<br \/>\n      aprepitant (0.5%). Those infusion-site reactions included infusion-site<br \/>\n      erythema, infusion-site pruritus, infusion-site pain, infusion-site<br \/>\n      induration, and infusion-site thrombophlebitis.\n    <\/p>\n<p>\n      <b>About Chemotherapy Induced Nausea and Vomiting<\/b> (<b>CINV)<\/b>\n    <\/p>\n<p>\n      Chemotherapy Induced Nausea and Vomiting (CINV) is a common side effect<br \/>\n      of chemotherapy caused by injured stomach cells that start the process<br \/>\n      of nausea and vomiting and can directly activate the area of the brain<br \/>\n      responsible for producing nausea and vomiting. The two main types of<br \/>\n      CINV are acute and delayed. Acute happens within the first 24 hours of<br \/>\n      receiving chemotherapy. Delayed happens from day 2 to day 5 after<br \/>\n      chemotherapy. The amount and timing of CINV can vary. Some<br \/>\n      chemotherapies cause acute nausea and vomiting. Others cause acute<br \/>\n      nausea and vomiting followed by another period of delayed nausea and<br \/>\n      vomiting.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.\u00a0Our focus is on pursuing<br \/>\n      research in immuno-oncology, and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=6b079b2260f4c9976790c928c414487e\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=769a7de2a628b6c054613032c70aaeb7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=2e8949fee6518b871ff4549394201308\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=deb4611d5df6c6ddbb72ed8f0421ad1e\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=8607cbc0a215df7c770e756924bd093c\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=5dd32db9eeaa8076d021b937028cdf64\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for EMEND (aprepitant) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend%2Femend_pi.pdf&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend%2Femend_pi.pdf&amp;index=7&amp;md5=fb61e9b0362614521cc464c7e6c3dea2\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/e\/emend\/emend_pi.pdf<\/a><br \/>\n      <b>and Patient Information for EMEND (aprepitant) at<\/b> <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend%2Femend_ppi.pdf&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend%2Femend_ppi.pdf&amp;index=8&amp;md5=cb33fd34e63417ed09ed44397c945d04\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/e\/emend\/emend_ppi.pdf<\/a>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for EMEND (fosaprepitant<br \/>\n      dimeglumine) for Injection at<span class=\"bwuline\"> <\/span><\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend_iv%2Femend_iv_pi.pdf&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend_iv%2Femend_iv_pi.pdf&amp;index=9&amp;md5=b883311ff677499b82ec677b28412af5\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/e\/emend_iv\/emend_iv_pi.pdf<\/a><br \/>\n      <b>and Patient Information for EMEND (fosaprepitant dimeglumine) for<br \/>\n      Injection at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend_iv%2Femend_iv_ppi.pdf&amp;esheet=51132387&amp;newsitemid=20150629005560&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fe%2Femend_iv%2Femend_iv_ppi.pdf&amp;index=10&amp;md5=3f83bfca7c29f6426b150588e84859a5\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/e\/emend_iv\/emend_iv_ppi.pdf<\/a>.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150629005560r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-740-1903<br \/>or<br \/>An        Phan, 908-255-6325<br \/>or<br \/>Investor:<br \/>Joseph Romanelli,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND \u00ae (fosaprepitant dimeglumine) for Injection, Merck\u2019s substance P\/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose EMEND for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) Annual Meeting<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745159","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND \u00ae (fosaprepitant dimeglumine) for Injection, Merck\u2019s substance P\/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose EMEND for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) Annual Meeting\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\\\/\",\"name\":\"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-06-29T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND \u00ae (fosaprepitant dimeglumine) for Injection, Merck\u2019s substance P\/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose EMEND for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) Annual Meeting","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:05+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/","name":"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-06-29T07:30:00+00:00","dateModified":"2025-11-07T06:25:05+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-injection-regimen-met-primary-endpoint-in-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-re\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Phase 3 Study of Single-Dose EMEND\u00ae (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4798b45d-258a-4885-a141-56d3a0cbf326","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745159\/revisions"}],"predecessor-version":[{"id":3674625,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745159\/revisions\/3674625"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745159"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}